Award
Definitive Contract #75N93020C00054
Definitive Contract Award to The Leland Stanford Junior University for COVID-19 Antiviral Development
Buyer
National Institutes of Health
Award Amount
$27,534,218.95
Ceiling
$38,210,700.95
Period of Performance
Sep 01, 2020 – May 31, 2030
Identifier
75N93020C00054
NAICS
541715
The awarded definitive contract, valued at $23,216,066, was granted to The Leland Stanford Junior University by the Department of Health and Human Services (HHS) to develop small synthetic chemical molecules aimed at treating viral infections, particularly in the context of COVID-19. The recipient, an esteemed educational institution, will leverage its significant expertise in medicinal chemistry and collaboration with various subcontractors to fulfill the contract's objectives. This contract, which is not subject to a set-aside designation, is vital for advancing antiviral research and development, contributing significantly to public health efforts amidst the pandemic. The work includes in vitro assessments of antiviral compounds, under a timeline extending from September 1, 2020, to August 31, 2025. The contract was awarded through full and open competition, ensuring broad participation and selection of qualified candidates.
Description
EO14398 TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS